A chronic multiple ascending dose phase Ib trial of Coversin in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2016
At a glance
- Drugs Coversin (Primary)
- Indications Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions
- 05 Dec 2016 Results published in an Akari Therapeutics media release.
- 12 Sep 2016 According to an Akari Therapeutics media release, the US FDA granted an orphan drug designation to coversin for the treatment of PNH.
- 06 Jul 2016 According to Akari Therapeutics media release, this trial is being conducted at Hammersmith Medicines Research Ltd, in London.